These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9465947)

  • 1. [Current status of the clinical development of MR contrast media].
    Laniado M; Kopp AF
    Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of action of liver contrast agents: impact for clinical use.
    Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-enhanced MR imaging of the liver.
    Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
    J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
    Mintorovitch J; Shamsi K
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
    Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
    Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
    Reimer P; Schneider G; Schima W
    Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging.
    Wang YX
    World J Gastroenterol; 2015 Dec; 21(47):13400-2. PubMed ID: 26715826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal nodular hyperplasia of the liver: serial MRI with Gd-DOTA, superparamagnetic iron oxide, and Gd-EOB-DTPA.
    Kacl GM; Hagspiel KD; Marincek B
    Abdom Imaging; 1997; 22(3):264-7. PubMed ID: 9107647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.
    Laurent S; Elst LV; Muller RN
    Contrast Media Mol Imaging; 2006; 1(3):128-37. PubMed ID: 17193689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume.
    Reimer P; Schuierer G; Balzer T; Peters PE
    Magn Reson Med; 1995 Nov; 34(5):694-7. PubMed ID: 8544689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver-specific MR imaging contrast agents.
    Hahn PF; Saini S
    Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis.
    Wiesinger B; Kehlbach R; Hemsen J; Bebin J; Bantleon R; Schwenzer N; Spira D; Claussen CD; Wiskirchen J
    Invest Radiol; 2011 Jan; 46(1):71-6. PubMed ID: 21139503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The magnetic properties of some materials affecting MR images.
    Josephson L; Bigler J; White D
    Magn Reson Med; 1991 Dec; 22(2):204-8; discussion 213-5. PubMed ID: 1812347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organ specific MRI contrast media in general practice].
    Schima W
    Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
    Rofsky NM; Earls JP
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MultiHance: help or hype?
    Bartolozzi C; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S151-9. PubMed ID: 10608411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.